|
Volumn 69, Issue 3, 2002, Pages 244-248
|
Which second-line treatments are optimal in psoriatic arthritis?
|
Author keywords
Controlled studies; Disease modifying; Psoriatic arthritis
|
Indexed keywords
ANTIMALARIAL AGENT;
AZATHIOPRINE;
CYCLOSPORIN;
ETANERCEPT;
GOLD;
HYDROXYCHLOROQUINE;
INFLIXIMAB;
METHOTREXATE;
NONSTEROID ANTIINFLAMMATORY AGENT;
SALAZOSULFAPYRIDINE;
ANTIRHEUMATIC AGENT;
CAUCASIAN;
CLINICAL TRIAL;
CREATININE BLOOD LEVEL;
DIFFERENTIAL DIAGNOSIS;
DOSE RESPONSE;
DRUG CHOICE;
DRUG WITHDRAWAL;
EDITORIAL;
HUMAN;
HYPERTENSION;
PREVALENCE;
PSORIATIC ARTHRITIS;
RHEUMATOID ARTHRITIS;
SIDE EFFECT;
SKIN DEFECT;
TREATMENT INDICATION;
TREATMENT PLANNING;
VALIDATION PROCESS;
CONTROLLED CLINICAL TRIAL;
ANTIRHEUMATIC AGENTS;
ARTHRITIS, PSORIATIC;
CONTROLLED CLINICAL TRIALS;
HUMANS;
|
EID: 0035991127
PISSN: 1297319X
EISSN: None
Source Type: Journal
DOI: 10.1016/S1297-319X(02)00388-3 Document Type: Editorial |
Times cited : (5)
|
References (30)
|